Medetomidine has become a popular choice for anesthetizing rats during long-lasting sessions of blood-oxygen-level dependent (BOLD) functional magnetic resonance imaging (fMRI). Despite this, it has not yet been established how commonly reported fMRI readouts evolve over several hours of medetomidine anesthesia and how they are affected by the precise timing, dose, and route of administration. We used four different protocols of medetomidine administration to anesthetize rats for up to six hours and repeatedly evaluated somatosensory stimulus-evoked BOLD responses and resting state functional connectivity throughout. We found that the temporal evolution of fMRI readouts strongly depended on the method of administration. Protocols that combined an initial medetomidine bolus (0.05 mg/kg) together with a subsequent continuous infusion (0.1 mg/kg/h) led to temporally stable measures of stimulus-evoked activity and functional connectivity. However, when the bolus was omitted, or the dose of medetomidine lowered, the measures attenuated in a time-dependent manner. We conclude that medetomidine can sustain consistent fMRI readouts for up to six hours of anesthesia, but only with an appropriate administration protocol. This factor should be considered for the design and interpretation of future preclinical fMRI studies in rats.
Introduction
Functional magnetic resonance imaging (fMRI), relying on blood-oxygen-level dependent (BOLD) contrast 1 , is being widely used for the non-invasive mapping of human brain function. Classically, fMRI has focused on the brain's response to a task or stimulus, but more recent task-free (resting state fMRI) approaches have explored spontaneous low frequency fluctuations in the BOLD signal 2,3 , and their role in the functional connectivity of healthy and diseased brains 4 . Since the advent of dedicated high-field MR systems, fMRI applications have expanded to experimental animals, especially rodents 5 . This is a promising development for translational preclinical research, since the same technique can be applied to both human patients and animal models. Additionally, the expanding capacity of small animal fMRI to be combined with genetic, pharmacological and surgical manipulations, as well as with electrophysiological and optical recordings, allows the exploration of increasingly complex neuroscientific questions [6] [7] [8] [9] .
Nevertheless, small animal fMRI poses a methodological challenge: it necessitates the subject's immobility for long imaging times. Animals can be restrained and habituated to head fixation and MR scanner noise, but this is laborious for the researcher, and often stressful for the animal [10] [11] [12] .
Thus, ethical and practical considerations mandate the use of anesthesia in the majority of small animal fMRI studies. Unfortunately, anesthetics confound fMRI measurements in multiple ways: they may alter neural activity, affect systemic cardiorespiratory physiology, and interfere with cerebral vasculature and neurovascular coupling-the very mechanism giving rise to the BOLD contrast 13, 14 . Therefore, there is a need for an anesthetic protocol that ideally provides sufficient, long-lasting sedation, while maintaining neural activity and neurovascular coupling. In pursuit of the above properties, researchers have tried multiple anesthetic agents, including α-chloralose, medetomidine, isoflurane, propofol, urethane, and ketamine-xylazine. These agents have varying effects on the neurovascular system, with each of them presenting a unique set of benefits and drawbacks for fMRI applications [12] [13] [14] [15] [16] [17] [18] . This has led to a substantial diversity in anesthetic protocols used for rodent fMRI, compromising the comparability and reproducibility of results.
Of the above anesthetics, the sedative agent medetomidine-a highly selective α2-adrenergic agonist-holds perhaps the most promise for becoming a routine choice for fMRI applications in rats. Medetomidine comes as an equal mixture of two enantiomers, with the dextro-isomer, dexmedetomidine, being the active component 19, 20 . Dexmedetomidine decreases the activity of noradrenergic neurons in the locus coeruleus, producing a state that mimics non-REM sleep 21 .
Conveniently, the drug's effects are reversible by a specific α2-adrenergic antagonist-atipamezole 19, 20 . A protocol based on the continuous infusion of medetomidine, first introduced by Weber et al. in 2005 22 , presents several advantages for fMRI studies: it sedates rats for several hours, leads to robust stimulus-evoked BOLD responses, allows for easy subcutaneous (SC) administration, avoids the need for intubation, and can be used for longitudinal studies with multiple fMRI sessions 23 . Other research groups have since confirmed the benefits of medetomidine infusion and expanded its usage to resting state fMRI [24] [25] [26] [27] . Medetomidine anesthesia is currently an established practice for rat fMRI, with at least 40 published articles reporting the use of the original medetomidine protocol, or variations of it ( Supplementary Table S1 ). Its use is expected to rise, owing to the practical advantages and to the increasing availability of techniques that can be combined with rat fMRI.
However, there are several concerns revolving around the duration and stability of medetomidine anesthesia. Medetomidine administration is always preceded by an inhalable gas anesthetic, usually isoflurane, which is used for anesthesia induction and animal preparation. Isoflurane alters brain metabolism 28 , strongly suppresses stimulus-evoked hemodynamic responses [29] [30] [31] , and may introduce widespread correlations in functional connectivity metrics 12, 27, 32 ; the possibility of these effects lingering long after isoflurane discontinuation cannot be excluded 33 . Then there is the issue of medetomidine itself, which is usually given in two steps: first as a bolus loading dose and then as a continuous infusion. Due to the drug's strong α2-adrenergic effects 20 , these actions are expected to time-dependently alter hemodynamic parameters, which could in turn affect BOLD-based readouts.
Another important concern is the restricted duration of anesthesia, with animals reported to spontaneously wake up despite the continuous infusion of medetomidine. Tolerance to the drug's sedative effects has been blamed for this, with researchers proposing to counter it by stepping up the infusion rate 25 . All the above issues are further compounded by the lack of consensus regarding the exact administration scheme; protocols vary in administration route and dose, while some researchers choose to omit the bolus (see Supplementary Table S1 ).
These concerns imply that commonly reported fMRI readouts, namely stimulus-evoked BOLD responses and resting state functional connectivity (RSFC), might not be stable over long-lasting imaging sessions. It is unclear when a steady state is reached by these readouts, for how long it is maintained, and how it is affected by various medetomidine administration choices. An answer to these questions would enable researchers to design rat fMRI experiments in a way that maximizes the duration of the steady state. This would increase the available experimental time, decrease variance, and ultimately reduce the total number of required animals, all the while promoting comparability among studies.
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To achieve the above goals, we examined how stimulus-evoked BOLD responses and RSFC evolve over time during medetomidine anesthesia. We tested four different protocols for medetomidine administration ( Table 1 , Fig. 1a ) on two separate sessions: firstly on a laboratory bench and secondly inside a small animal MR-system. During the latter session, we performed multiple repeated fMRI measurements (runs), with consecutive runs being alternated between somatosensory stimulus-evoked fMRI with electrical forepaw stimulation (EFS-fMRI) and resting state fMRI (RS-fMRI) (see Fig. 1b -c). The acquired runs, 283 EFS-fMRI and 295 RS-fMRI in total, spanned a period of 0.5 -6 hours relative to the start of medetomidine administration. For each medetomidine protocol, we report the achieved duration of anesthesia and the following measures across time: heart and respiratory rates (HR and RR); localization and amplitude of stimulus-evoked responses; strength and structure of RSFC. Based on our findings, we make recommendations regarding the administration protocol of medetomidine and the timing of fMRI experiments within the protocol. 
Results

Anesthesia duration and physiology
Out of all 48 anesthesia sessions, 27 lasted for the full six hours, while 21 ended with a spontaneous wake-up (spontaneous movement for bench sessions; rapid rise in RR for fMRI sessions). These wake-up incidents occurred across session types (8/24 bench; 13/24 fMRI) and medetomidine protocols (4, 6, 7, and 4 out of 12, for protocols 1 -4 respectively). However, only a few of those occurred early, with 35/48 sessions (72.9%) exceeding five hours in duration ( Fig. 2, left) . The HR and RR followed similar temporal trends across all four medetomidine protocols ( Fig. 2, right) . HR decreased rapidly after the introduction of medetomidine, dropping by approximately 50% within the first hour of anesthesia. After that it showed only a slight tendency to gradually recover over time. The RR also underwent rapid changes in the first hour: it started at 40-70 bpm under isoflurane, decreased in response to medetomidine introduction, and gradually recovered following the discontinuation of isoflurane. As was the case with HR, it remained mostly stable after the first hour.
Areas activated by the stimulus
For each EFS-fMRI run we identified the active areas using a first-level general linear model analysis. The thresholded statistical maps (cluster threshold, z > 3.1, p = 0.05) were binarized (1 for active voxels, 0 elsewhere) and averaged across all EFS-fMRI runs to produce an activation probability map. The probability map revealed a consistently active cluster, anatomically corresponding to the left (contralateral to the stimulus) forelimb region of the primary somatosensory cortex-abbreviated as S1FL ( Fig. 3a left) . This cluster's center was active in 85.16% of all EFS-fMRI runs, whereas no other area was active in more than 7% of runs. To ensure that there was no systematic shift in the location of the active S1FL cluster, the 283 first-level activation maps were split into 12 groups according to the applied medetomidine protocol and the time since 
Shape and strength of stimulus-evoked responses
The portion of the S1FL that was significantly active in at least 30% of all 283 EFS-fMRI runs was taken as a functionally-defined region-of-interest (ROI). For each EFS-fMRI run, this ROI's mean BOLD time course was extracted, normalized to the pre-stimulus baseline, and averaged across stimulation blocks to produce an event-related average. This was used to extract the peak % signal change (peak ΔBOLD), as a measure of stimulus-evoked BOLD response strength (Fig. 3b ). The examination of event-related averages revealed that the shape of S1FL BOLD responses was very similar across the four medetomidine protocols (Fig. 3c ). The signal exhibited a sharp peak after stimulus onset, followed by a plateau lasting till the end of the 30 s stimulation. The time-to-peak was found to be consistently about 3 s for all protocols-shorter than what is assumed by the default hemodynamic response functions of most fMRI analysis packages ( Fig. 3d ).
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The peak ΔBOLD exhibited varying temporal trends depending on the medetomidine protocol ( Fig.   4a -b). Protocol 2 (IV with bolus) led to the most stable BOLD responses, with mean peak ΔBOLD of 2.4%, independent of time (p = 0.61, Likelihood Ratio Test). Omitting the bolus (protocol 3, IV no bolus), or lowering the medetomidine dose (protocol 4, IV lower dose), led to stronger early responses at around 4 -4.5%, but these were not sustainable over time: peak ΔBOLD decayed with negative slopes of 0.43%/hour (p < 0.001) and 0.47%/hour (p < 0.001) respectively. Protocol 1 (SC with bolus) also exhibited a decreasing temporal trend, but with a smaller slope (-0.24%/hour, p = 0.02), and with the effect being driven by four exceptionally strong early BOLD responses in two of the rats. In general, and despite their differing temporal trends, all four protocols converged to a mean peak ΔBOLD of around 2.5% after two hours of medetomidine anesthesia (Fig. 4c ).
Resting state functional connectivity
RSFC was probed by examining the pair-wise correlations between the BOLD time courses of 28 anatomically defined ROIs ( Fig. 5a ). Examination of the pair-wise correlation matrices (Fig. 5b ), and of their network representations ( Fig. 5c ), showed that the hierarchical structure of the network, i.e.
the strength of individual connections relative to each other, was consistent over time for all medetomidine protocols. The network's global RSFC-the mean correlation (Fisher's Z-score) across all unique ROI pairs-was computed for all RS-fMRI runs, and tested for time dependence ( Fig. 5d ). Bolus-based medetomidine administration (protocols 1, 2 and 4) provided stable global RSFC throughout the six hours of anesthesia: Z-scores remained at 0.57 ± 0.27 (mean ± s.d.), 0.44 ± 0.17, and 0.34 ± 0.12 respectively, and exhibited no significant temporal trends (p = 0.80 for protocol 1; p = 0.17 for protocol 2; p = 0.09 for protocol 4). When the bolus was omitted (protocol 3, IV no bolus), global RSFC was stronger during the early period (0.85 ± 0.30), but decreased timedependently with a slope of -0.07/hour (p = 0.02).
Discussion
In the present study we evaluated the capacity of medetomidine-administered through four different protocols-to anesthetize rats for up to six hours and sustain temporally stable fMRI measures of stimulus-evoked activity and functional connectivity. We found that anesthesia duration exceeded five hours in most sessions (35/48 or 72.9%; Fig. 2 , left), heart and respiratory rates were mostly stable after the first hour of anesthesia ( Fig. 2, right) , and the majority of performed EFS-fMRI runs (241/283 or 85.16%) led to a significant and selective activation of the expected cortical area (Fig. 3a) . However, the temporal stability of both stimulus-evoked activity and functional connectivity was observed to strongly depend on the protocol of medetomidine administration ( Fig. 4 and 5 ).
Limited anesthesia duration has been referred to as a drawback of medetomidine protocols 34 , even though the exact duration is not reported in most papers. According to a study that has addressed this issue, rats anesthetized by constant IV infusion woke up spontaneously 3.5-4 hours into the experiment 25 . However, the rats in that study were tracheotomized and mechanically ventilated, while most rat fMRI experiments-including ours-are conducted in freely breathing animals. The anesthesia durations achieved in our experiments should satisfy the needs of most researchers.
That said, the risk of spontaneous wake-ups must be taken into consideration. In our study, these wake-ups occurred more often in fMRI than in bench sessions (13/24 versus 8/24)-a possible effect of the scanner's acoustic noise, and were typically preceded by an increase in RR and arrhythmic breathing. If early wake-ups have to be avoided, other administration practices may be warranted, such as stepping up the infusion rate 25 , or adding a constant low dose of isoflurane throughout the imaging session 35 . The latter strategy has gained popularity in recent years, on the basis that it provides near-normal physiological conditions 35 and protects against epileptic seizures-which have been reported in animals with medetomidine-only anesthesia 36 . However, this might require mechanical ventilation, since even low doses of isoflurane, when combined with medetomidine, have been shown to suppress the amplitude of stimulus-evoked BOLD responses in spontaneously breathing rats 37 .
The recorded cardiorespiratory parameters (HR and RR) underwent rapid changes in the first hour of anesthesia, but stabilized thereafter ( Fig. 2, right) . The observed changes agree with medetomidine pharmacology and with previous rat fMRI studies 20, 23, 38 . The decrease in HR immediately after medetomidine injection can be attributed to its well-described α2-adrenergic effects. Since the respiratory effects of medetomidine alone are considered to be minor, the observed initial drop in RR was probably caused by medetomidine enhancing the potency of isoflurane-and thus amplifying isoflurane-induced respiratory depression 20 . This interpretation is supported by the gradual recovery of RR following the discontinuation of isoflurane.
The EFS-evoked activation of the contralateral S1FL ( Fig. 3) is described by numerous other rat fMRI studies using the same stimulus [23] [24] [25] . For a subset of trials, these studies have also reported activations in the secondary somatosensory area and in sensory thalamic nuclei. If we increase statistical power by grouping multiple fMRI runs in a second-level analysis, we also find the same areas being responsive to EFS (see Supplementary Fig. S2 ). The shape of the EFS-evoked BOLD 8 response in the S1FL (sharp peak at about 3 s after the onset of stimulation, followed by a plateau sustained till the end of EFS period; see Fig. 3c ) is consistent with previous rat fMRI studies 24, 39 , but differs considerably from what would be expected based on the standard human double-gamma hemodynamic response function 40 . Specifically, the response in medetomidine-anesthetized rats exhibits faster kinetics (Fig. 3d ). The reasons for that could be diverse, including the different species, the use of anesthesia, the higher magnetic field strength utilized in rodent studies, or a combination of these factors. Nevertheless, since rat fMRI with medetomidine is becoming such a common practice (see Supplementary Table S1 ), future studies should focus on determining the optimal response function for this paradigm.
The temporal evolution of peak stimulus-evoked responses exhibited an interesting dependence on the medetomidine administrations protocol ( Fig. 4) : the peak ΔBOLD differed significantly among protocols in the early two hours of anesthesia, before eventually converging to the same value. At this point we would like to emphasize several limitations of the present study. Importantly, we have not measured blood concentrations of medetomidine, and thus we cannot directly verify our interpretation of the dose-dependent effects. Moreover, we have no way of dissecting the vascular 9 and neuronal contributions to the observed effects on BOLD readouts: we lack electrophysiological recordings of neural activity and important measures of vascular physiology, such as cerebral blood flow and arterial blood gas concentrations. We also lack fMRI data for very early time points: the earliest fMRI runs were acquired 30 -50 minutes after the onset of medetomidine administration, due to the time spent for animal positioning, structural image acquisition and shimming, and the required overlap between medetomidine administration and isoflurane anesthesia. This delay was most pronounced for protocol 3, during which the said overlap was necessarily prolonged.
Despite these limitations, our study does provide an empirical answer to the question of how BOLD readouts evolve over long-lasting medetomidine anesthesia sessions, allowing us to recommend best practices for maximizing the duration of the steady state. Whenever temporal stability is deemed crucial, a bolus administration of medetomidine and a dosage according to the originally published protocol 23 are strongly recommended. Both IV and SC routes can be considered: IV administration leads to less variance in the initial two hours, but SC is easier to implement. Although we lack fMRI data from the first hour of anesthesia, we would advise against performing functional imaging within this period, considering the rapid changes in cardio-respiratory physiology. In conclusion, the recommended dosage (protocols 1 and 2) is clearly sufficient to provide consistent measures of stimulus-evoked activity and functional connectivity in the time period from one to six hours since the bolus. We do not claim that this administration protocol is necessarily the best choice for rat fMRI, since our study did not include all existing (see Supplementary Table S1 ) or possible administration protocols. It is however reasonable to consider it as the current 'default' choice, in light of the wealth of available data, and in the interest of promoting comparability among studies. into four equally sized groups, each assigned to a different protocol of medetomidine administration (see Table 1 ). No animal was excluded from the experiments or from the analysis. The investigators
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were not blind to the group allocation.
Anesthesia and monitoring
Each animal was anesthetized on two sessions separated by a minimum of two weeks. The first session took place on a laboratory bench-top to accommodate unrestricted access to the animal and close monitoring of anesthesia duration and cardio-respiratory physiology (bench session). The functional imaging took place during the second session, performed inside a dedicated small animal MR system (fMRI session). All applied anesthetic protocols followed the same general outline, with isoflurane being used during preparation, and medetomidine during data acquisition (Fig. 1a ).
Unconsciousness was induced in a chamber filled with 5% isoflurane and maintained throughout preparation with 2-3% isoflurane supplied through a nose cone. The eyes were covered with ophthalmic ointment to prevent them from drying. A cannula was inserted in the SC tissue of the left flank (protocol 1) or in a tail vein (protocols 2 -4). Two subdermal needle electrodes were placed in the right forepaw, between the 2 nd and the 4 th digit. Monitoring equipment was attached, consisting of a rectal temperature probe, a pneumatic pressure sensor placed on the chest, and three SC needle electrodes for electrocardiogram (ECG). After fixing the aforementioned equipment with adhesive tape, the animal was transferred to a custom-built MRI-compatible rat bed.
Four different protocols of medetomidine administration were used: 1) SC with bolus; 2) IV with bolus; 3) IV no bolus; 4) IV lower dose. The detailed dosing for all protocols is given in Table 1 . For protocols 1, 2, and 4, medetomidine (Dorbene vet, Zoetis Deutschland GmbH, Germany) was initially given as a bolus loading dose, followed by a gradual reduction of isoflurane and its eventual discontinuation 10 min later; continuous infusion of medetomidine commenced 15 min after the bolus. The bolus was omitted for protocol 3, with continuous infusion starting directly after the preparation phase, and isoflurane being gradually reduced to zero over the course of 20 -25 min.
Attempts to shut off isoflurane earlier led to fast breathing, indicative of an imminent wake-up (bench sessions). All doses were delivered using an MRI-compatible infusion pump (PHD 2000
Infuse/Withdraw; Harvard apparatus, Holliston, Massachusetts, USA). Since the start of medetomidine administration, heart rate (HR), respiratory rate (RR), and rectal temperature were monitored using the MR-compatible Model 1030 monitoring and gating system (Small Animal Instruments Inc., Stony Brook, NY 11790, USA). Rectal temperature was kept at 36.5 ± 1°C using a 11 pad heated by circulating water. Anesthesia was maintained for six hours since the start of medetomidine administration, except for sessions in which the rat spontaneously woke up earlier.
For bench sessions, such wake-ups were identified as spontaneous movements of the rat, and were found to be always preceded by the RR getting progressively faster and irregular. Since direct observation of minor animal movement is challenging during fMRI, the endpoint for fMRI sessions was set based on respiration (RR > 90/min, irregular, and continuously rising for at least 2 min).
Anesthesia duration was defined as the time from the start of medetomidine administration (time = 0) till one of the aforementioned endpoints: spontaneous movement, rapid rise in RR, or passage of six hours. Upon reaching an endpoint, the animal was provided with 2% isoflurane through the nose cone and was disconnected from all electrodes, cannulas, and monitoring equipment. 
MRI acquisition
The fMRI sessions were performed inside a 9.4 Tesla Bruker BioSpec MR system, equipped with the BGA12 gradient, and operated via Paravision 6.0.1 software. Signal was transmitted via a resonator volume coil (inner diameter 86 mm) and received by a rat brain 4-channel coil array (all equipment and software from Bruker Biospin MRI GmbH, Ettlingen, Germany). Approximately 10 min after the discontinuation of isoflurane, the rat was positioned in the isocenter of the MR system, with its body lying supinely and its head fixed with the help of a bite bar. After obtaining low-resolution images for object localization, a T2-weighted structural image was acquired using a TurboRARE sequence between somatosensory fMRI with electrical forepaw stimulation (EFS-fMRI) and resting state fMRI (RS-fMRI) with no stimulus (Fig. 1b) . This resulted in a total number of 283 EFS-fMRI and 295 RS-fMRI runs across all rats, spanning from 0.5 up to 6 hours since the start of medetomidine administration. EFS-fMRI runs included a baseline period of 60 s, followed by stimulation of the right forepaw in three 30 s blocks-each paired with 60 s of rest ( Fig. 1c ). Each stimulus block comprised square unipolar pulses with 3 mA amplitude and 0.3 ms pulse width, delivered at 9 Hz (Stimulus Generator 4002, Multi Channel Systems MCS GmbH, Reutlingen, Germany). The above parameters were chosen based on previous EFS studies in medetomidine-anesthetized rats 24, 25, 43 .
MRI preprocessing
All MR images were first exported from Paravision to DICOM format and then converted to NIfTI (Neuroimaging Informatics Technology Initiative; http://nifti.nimh.nih.gov) using the dcm2nii (https://www.nitrc.org/projects/dcm2nii/) tool. The structural T2-weighted images were used to construct a study template with the help of the Advanced Normalization Tools software-ANTs (http://stnava.github.io/ANTs/). The structural image of one of the rats was chosen as the target reference space. Every other structural image was registered to the target in two steps: a linear rigid (3 translations and 3 rotations), and a non-linear symmetric diffeomorphic (SyN) registration 44 . All 24 structural images were averaged in the reference space to produce a mean anatomical image. A down-sampled (0.2 x 0.2 x 0.5 mm 3 ) version of this image was used to create a brain mask and served as the study template to which all functional datasets were eventually registered. The fMRI image series were preprocessed using functions from multiple neuroimaging toolkits, combined into a pipeline with python's Nipype library 45 . Images were corrected for slice timing with FSL (FMRIB Software Library, https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/) and temporally filtered with AFNI (https://afni.nimh.nih.gov/). A high-pass filter of 0.01 Hz was used to remove slow temporal drifts, with an additional low-pass filter of 0.15 Hz being applied to RS-fMRI datasets only. Spatial smoothing (FSL) was performed using a 0.5 mm 3D Gaussian kernel. We chose to skip motion correction and regression of nuisance variables, as these preprocessing steps were shown to have little effect in anesthetized and head-fixed rodents 46 . A rigid transformation matrix was calculated between the mean image of each functional run and the native structural image. This matrix was combined with the previously calculated linear and non-linear transforms into a composite warp file, which was used to transform the preprocessed fMRI datasets into the study template space (ANTs).
fMRI analysis and statistics
Areas activated during each EFS-fMRI run were identified via a first-level general linear model analysis carried out using FEAT (FMRI Expert Analysis Tool) Version 6.00, part of FSL 47 . The stimulus time course (1 during stimulation, 0 elsewhere) was convolved with a standard doublegamma hemodynamic response function to generate the model predictor. The resulting statistical maps were masked for brain, thresholded non-parametrically using clusters determined by z > 3.1 and a corrected cluster significance threshold of p = 0.05, binarized, and averaged across all 283 EFS-fMRI runs to construct an overall activation probability map. The region active in at least 30% of all EFS-fMRI runs (contralateral S1FL; see Fig. 3a ) was taken as a region-of-interest (ROI). This ROI's mean BOLD time course was extracted from each EFS-fMRI run, normalized to the prestimulus baseline, and averaged across the three stimulation blocks to produce an event-related average. The peak % signal change (peak ΔBOLD) was extracted from the event-related average, as a measure of BOLD response strength (Fig. 3b) . We also performed a second-level fixed-effects analysis (FEAT) for each medetomidine protocol, by pooling the corresponding EFS-fMRI runs and computing the mean group effect. The resulting statistical maps were masked for brain and thresholded non-parametrically using GRF-theory-based maximum height thresholding with a (corrected) significance threshold of P=0.05.
Resting state functional connectivity (RSFC) analysis was performed using in-house python scripts.
All 295 preprocessed RS-fMRI datasets were normalized by subtracting the temporal mean and dividing by the standard deviation. Normalized BOLD signal time courses were extracted from 28
ROIs (14 on each hemisphere), manually delineated based on the Paxinos-Watson rat brain atlas 48 (see Fig. 5a Fig. 1. Anesthetic protocols and fMRI acquisition. (a) The general outline of the applied anesthetic protocols. For all four protocols (see Table 1 ), isoflurane was used to induce unconsciousness (5%) and during animal preparation (2-3%). For protocols 1, 2, and 4, a bolus of medetomidine was given after the preparation phase, followed by a gradual reduction of isoflurane and its eventual discontinuation 10 min later; continuous infusion of medetomidine commenced 15 min after the bolus. The bolus was omitted for protocol 3, with continuous infusion starting directly after preparation, and isoflurane being gradually reduced to zero over the course of 20 -25 min. Anesthesia was maintained for a maximum of six hours since the start of medetomidine administration (time = 0). In the end, animals were provided with 2% isoflurane and freed from all equipment. Atipamezole was injected SC to antagonize medetomidine effects and to facilitate a smooth recovery. 
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